Scrip: industry news and insights
GSK’s Dostarlimab Gets EU Nod For Endometrial Cancer
26 Feb 2021
While its NDA languishes at the US Food and Drug Administration, the EMA’s CHMP has said yes to dostarlimab’s marketing...
Pfizer Inc., GlaxoSmithKline PLC, Allergan PLC and Eli Lilly & Co. are among big pharma firms facing generic competition to blockbuster brands, while AbbVie Inc. and Roche have got biosimilar rivals to worry about.
New drug launches have increased over the past couple of years, but few have reached blockbuster status yet. Meanwhile, China’s increasing appetite (and willingness to pay) for therapeutic innovation was a positive for several big pharma companies in the first quarter. Scrip’s webinar takes a deep dive into the key issues and trends emerging from industry earnings calls.
Scrip: industry news and insights
26 Feb 2021
While its NDA languishes at the US Food and Drug Administration, the EMA’s CHMP has said yes to dostarlimab’s marketing...
Scrip: industry news and insights
By Anju Ghangurde 26 Feb 2021
Merck & Co. executive outlines how the company could sustain a “compliant supply performance” amid the pandemic, while senior officials...
Scrip: industry news and insights
By John Davis 26 Feb 2021
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies...
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: